- 【Updated on May 12, 2025】 Integration of CiNii Dissertations and CiNii Books into CiNii Research
- Trial version of CiNii Research Knowledge Graph Search feature is available on CiNii Labs
- 【Updated on June 30, 2025】Suspension and deletion of data provided by Nikkei BP
- Regarding the recording of “Research Data” and “Evidence Data”
Update of <sup>18</sup>F-flurpiridaz
-
- Matsumoto Naoya
- Department of Cardiology, Nihon University Hospital
Search this article
Description
The novel positron emission tomography (PET) myocardial perfusion imaging tracer, 18F-flurpiridaz (flurpiridaz), was discussed in 2023 at the Annals of Nuclear Cardiology. In a Phase III trial in 2020 by Maddahi et al., flurpiridaz demonstrated higher sensitivity (71.9%) than 99mTc-labeled single photon emission computed tomography (SPECT) (53.7%) for detecting ≥50% coronary artery stenosis but did not meet the non-inferiority criterion in specificity. This led to a second Phase III trial, the AURORA trial, which showed flurpiridaz PET to be more sensitive (80.3%) and not inferior (63.8%) in specificity compared to SPECT. The trial highlighted flurpiridaz's superior diagnostic accuracy, especially in women and obese patients. The tracer's ability to measure coronary blood flow reserve suggests its potential future use in clinical practice, possibly offering more accurate functional ischemia diagnostics and predicting cardiac events. The findings indicate that 18F-flurpiridaz could be a significant advancement in coronary artery disease diagnosis.
Journal
-
- Annals of Nuclear Cardiology
-
Annals of Nuclear Cardiology 10 (1), 49-50, 2024
Japanese Society of Nuclear Cardiology
- Tweet
Keywords
Details 詳細情報について
-
- CRID
- 1390864966209103616
-
- ISSN
- 24241741
- 21893926
-
- Text Lang
- en
-
- Data Source
-
- JaLC
- Crossref
-
- Abstract License Flag
- Disallowed